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ABSTRACT
ObjeCtive
To investigate the regulatory approval of new medical 
devices.
Design
Cross sectional study of new medical devices reported 
in the biomedical literature.
Data sOurCes
PubMed was searched between 1 January 2000 and 31 
December 2004 to identify clinical studies of new 
medical devices. The search was carried out during 
this period to allow time for regulatory approval.
eligibility Criteria fOr stuDy seleCtiOn
Articles were included if they reported a clinical study 
of a new medical device and there was no evidence of 
a previous clinical study in the literature. We defined a 
medical device according to the US Food and Drug 
Administration as an “instrument, apparatus, 
implement, machine, contrivance, implant, in vitro 
reagent, or other similar or related article.”
Main OutCOMe Measures
Type of device, target specialty, and involvement of 
academia or of industry for each clinical study. The FDA 
medical databases were then searched for clearance 
or approval relevant to the device.
results
 5574 titles and abstracts were screened, 493 full text 
articles assessed for eligibility, and 218 clinical studies 
of new medical devices included. In all, 99/218 (45%) 
of the devices described in clinical studies ultimately 
received regulatory clearance or approval. These 
included 510(k) clearance for devices determined to be 
“substantially equivalent” to another legally marketed 
device (78/99; 79%), premarket approval for high risk 
devices (17/99; 17%), and others (4/99; 4%). Of these, 
43 devices (43/99; 43%) were actually cleared or 
approved before a clinical study was published.
COnClusiOns
We identified a multitude of new medical devices in 
clinical studies, almost half of which received 
regulatory clearance or approval. The 510(k) pathway 
was most commonly used, and clearance often 
preceded the first published clinical study.
Introduction
The introduction of new medical devices is fundamen-
tal to the advancement of healthcare. Historically, such 
devices have been adopted with little scientific evi-
dence to support their use.1  Although many devices 
have greatly improved clinical outcomes, not all are 
beneficial and some may be harmful. To this end most 
jurisdictions have developed regulatory bodies, such as 
the US Food and Drug Administration, that ensure the 
safety and effectiveness of new medical devices.2 These 
regulatory bodies must also act in an efficient and 
timely manner such that patients are not deprived from 
beneficial innovations.
The process by which new high risk medical devices 
find their way from bench to bedside is well estab-
lished: the development of the device resulting in a 
first-in-human study; the evaluation of the device in 
clinical trials, culminating in a regulatory approval for 
use; and the adoption of the device.3  Although high risk 
devices warrant considerable scientific evidence for 
their safety and effectiveness before regulatory 
approval, the pathway for lower risk devices is less 
stringent, allowing for their more rapid approval.4-6
We investigated the use of these distinct regulatory 
approval pathways for new medical devices.
Methods
We performed a cross sectional study of new medical 
devices reported in the literature to determine whether 
they received regulatory approval, and the relative con-
tributions of academia and industry in this process. 
Before searching for evidence of regulatory approval, 
we identified clinical studies of devices, allowing us to 
capture those devices that failed to receive approval.
We defined a medical device according to the FDA 
definition as an “instrument, apparatus, implement, 
machine, contrivance, implant, in vitro reagent, or 
other similar or related article.” If there was no evi-
dence of a previous clinical study of a device in the lit-
erature, we considered the device as new.
For each article reporting a clinical study of a new 
medical device, we defined academia and industry as 
being involved with the development of the device if a 
relation was described. If an entry could be found on 
the FDA medical device databases, we considered a 
device as having regulatory approval.
search strategy
The PubMed database was searched using the Boolean 
term: (device OR instrument OR apparatus OR implant 
OR “in vitro reagent” OR system) AND (“first in man” 
OR “first in human” OR “first experience” OR “first 
clinical” OR “early clinical” OR “early experience” OR 
“early human” OR “initial experience” OR “initial 
WhAT IS AlReAdy knoWn on ThIS TopIC
New medical devices have distinct regulatory approval pathways
WhAT ThIS STudy AddS
Almost half of the new medical devices described in the literature ultimately receive 
regulatory clearance or approval
The 510(k) pathway (a fast track system allowing regulatory approval of a device 
that is “substantially equivalent” to a predicate device) is most commonly used, 
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 clinical” OR “initial human” OR “preliminary clinical” 
OR “preliminary experience” OR “preliminary human” 
OR “Phase 1” OR “Phase I”). We selected this search 
term owing to efficiency and being able to identify the 
most relevant studies. The search was carried out 
between 1 January 2000 and 31 December 2004 to allow 
time for regulatory approval, as previous studies have 
suggested a long lag between the development of a 
device and subsequent regulatory approval.7 8
We included articles that reported a clinical study of 
a new medical device and excluded those that only 
reported a laboratory study of a device, because few 
such devices ultimately result in a clinical study.9 We 
also excluded articles if they reported on the novel use 
of an existing device, as we expected that most such 
devices would already have received regulatory 
approval.
Based on a pilot study, we estimated (between 1 
 January 2000 and 31 July 2000) that this search strategy 
would select sufficient articles to allow for meaningful 
analysis.
Two researchers initially screened titles and abstracts 
to identify relevant articles (HJM and CJP, checked by 
AHH and APM). We excluded articles if the title or 
abstract explicitly stated that the article was not origi-
nal research, related to drug development, related to an 
existing medical device, or a laboratory study. Full arti-
cles were subsequently obtained and further assessed 
for eligibility. In each instance we reviewed the refer-
ence list and searched the PubMed database using the 
device name to ensure that we did not miss a related 
previous clinical study (that would result in their exclu-
sion). Discrepancies were resolved by consensus.
Medical devices
For each clinical study of a new medical device, we 
determined the type of device, the target specialty, and 
the involvement of academia and of industry (HJM and 
CJP, checked by AHH and APM). The types of device 
were based on the FDA definition, and the target spe-
cialties were drawn from the FDA databases. We consid-
ered academia and industry to be involved in the 
development of a device if a relevant author affiliation, 
financial support, or provision of technology was 
described in the author affiliations, main text, or 
acknowledgments of the article. Discrepancies were 
resolved by consensus.
regulatory approvals
For each new medical device, we searched the FDA 
databases for a relevant regulatory clearance or 
approval. The FDA recognises several types of regula-
tory pathway depending on the nature of the device. 
Premarket notification (510(k)) is the regulatory path-
way if the device is “substantially equivalent” to a pred-
icate device and does not necessarily require clinical 
data. Premarket approval is the regulatory pathway if 
the device is “not substantially equivalent,” and 
requires reasonable evidence of safety and effective-
ness. Other regulatory pathways include humanitarian 
device exemption if the device is for use in patients with 
rare diseases or conditions. We searched the FDA 
510(k), premarket approval, and humanitarian device 
exemption databases using the device name, applicant 
name, and relevant keywords (HJM and CJP, checked by 
AHH and APM). We also searched Google for devices 
that may have been discontinued, withdrawn, or 
recalled. Search results were not limited to a date range, 
allowing for the identification of regulatory clearance or 
approval before the first published clinical study. All 
the searches were performed in August 2015, allowing a 
minimum of 10 years from publication to regulatory 
clearance or approval. Discrepancies were resolved by 
consensus.
statistical analysis
To compare differences in regulatory clearance or 
approval between the following groups we used the 
χ2 test: devices developed by industry alone versus aca-
demia alone; devices developed by both industry and 
academia versus academia alone; and devices devel-
oped by both industry and academia versus industry 
alone. Firstly, we compared the proportion of devices 
receiving any regulatory clearance or approval (versus 
no clearance or approval). Secondly, we compared the 
proportion of devices receiving 510(k) clearance (versus 
any other approval). We considered differences to be 
statistically significant if P was less than 0.05. All statis-
tical analyses were performed using SPSS 22.0 (IBM, 
NY, USA).
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
developing plans for design or implementation of the 
study. No patients were asked to advise on interpreta-
tion or writing up of results. There are no plans to dis-
seminate the results of the research to study participants 
or the relevant patient community.
Results
search strategy
In all, 5574 titles and abstracts were screened, 493 full 
text articles assessed for eligibility, and 218 clinical 
studies of new medical devices included (fig 1). 
Records identied in PubMed (n=5574)
Titles and abstracts screened (n=5574)
Full text articles assessed for eligibility (n=493)
Studies included in analysis (n=218)
Records excluded (n=5081)
Full text articles excluded (n=275):
  Not original research (n=6)
  Not a device (n=32)
  Not a clinical study (n=15)
  Not new (n=222)
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The   corresponding authors originated from 28 coun-
tries, but most were located in the United States (70/218; 
32%) and Germany (43/218; 20%).
Medical devices
Most of the medical devices reported were instruments 
(86/218; 39%) or implants (79/218; 36%) (table 1). Devices 
were developed by industry alone (140/218; 64%), 
 academia alone (46/218; 21%), or both (32/218; 15%).
regulatory approvals
Of the 218 devices described in clinical studies, 99 
(45%) ultimately received regulatory clearance or 
approval (table 2). These included 510(k) clearance 
(78/99; 79%), premarket approval (17/99; 17%), and 
humanitarian device exemption (4/99; 4%).
Regulatory clearance or approval was granted 
between April 1997 and September 2014. The median 
lag between publication of the clinical study and reg-
ulatory clearance or approval was 2 months (inter-
quartile range −10.8 to 26.3 months). Of these, 43 
devices (43/99; 43%) were actually cleared or approved 
before a clinical study was published; the median lag 
in these devices was −12.5 months (interquartile range 
−23.3 to −6.3 months).
Published clinical studies of devices that received 
regulatory clearance or approval were mostly case 
series’ comprising level 4 evidence (89/99; 90%).
statistical analysis
Devices were more likely to receive regulatory clearance 
or approval if developed by industry alone compared 
with academia alone (58% v 11%; P<0.001), or by both 
industry and academia compared with academia alone 
(41% v 11%; P=0.003). There was no significant differ-
ence in clearance or approval between devices devel-
oped by industry alone compared with both industry 
and academia (58% v 41%; P=0.114).
There was no significant difference in the proportion 
of 510(k) clearance and other approvals that were 
awarded to industry alone, industry and academia, or 
academia alone (P>0.1 in all cases).
discussion
We identified a multitude of new medical devices in 
clinical studies, almost half of which received regula-
tory approval. The 510(k) pathway was most commonly 
used, and devices often received regulatory clearance 
before the first published clinical study. The corollary is 
that many devices cleared for use in patients had no 
clinical data accessible in the literature to support their 
use. Published clinical studies were mostly case series’ 
comprising level 4 evidence. Without high quality clin-
ical data available, informed shared decision making 
on the use of new medical devices is difficult if not 
impossible.
The 510(k) pathway is a fast track system that allows 
the regulatory approval of a device that is “substantially 
equivalent” to a predicate device. A device is consid-
ered substantially equivalent if it has the same intended 
use as the predicate device and it has the same techno-
logical characteristics, or, if it has different technologi-
cal characteristics, information is provided that 
demonstrates that it is at least as safe and effective as 
the predicate device. Clinical studies are therefore not 
usually required.
The introduction of a device after it has been cleared 
through the 510(k) pathway is usually unstructured 
and variable.2  A device may be introduced in the form 
of a research study but, more often, may be published 
as a non-comparative trial without special institutional 
board review. Although many such devices are safe and 
effective, the dangers of this process are obvious and 
have been reported.10-13  The Balliol Collaboration has 
proposed the IDEAL model for safe innovation to deal 
table 1 | Characteristics of new medical devices, and whether they ultimately received 
regulatory clearance or approval, or not
Characteristics total (n=218)
Clearance or  
approval (n=99)
no clearance or 
approval (n=119)
Type of device:
 Imaging 31 11 20
 Implant 79 37 42
 Instrument 86 47 39
 Laboratory analysis 3 1 2
 Monitor 10 3 7
 Physiotherapy 7 0 7
 Other 2 0 2
Target specialty:
 Anesthesiology 5 2 3
 Cardiovascular 67 40 27
 Clinical chemistry 2 0 2
 Clinical toxicology 1 0 1
 Dental 2 0 2
 Ear, nose, and throat 12 3 9
 Gastroenterology and urology 19 7 12
 General and plastic surgery 22 11 11
 General hospital 8 2 6
 Haematology 2 1 1
 Neurology 15 6 9
 Obstetrics and gynaecology 11 6 5
 Ophthalmology 11 5 6
 Orthopaedics 22 10 12
 Physical medicine 6 0 6
 Radiology 13 6 7
table 2 | Development of new medical devices, and whether they ultimately received regulatory clearance or approval, 
and regulatory pathway used
Developer total (n=218)
Clearance or 





Academia alone 46 5 5 0 0
Academia and industry 32 13 10 1 2
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with this shortfall, the central tenet being that innova-
tion and evaluation can and should proceed together 
in an ordered and logical manner.2 14-18  Moreover, the 
FDA has recognised the need for reform and has 
announced a new vision for post-market surveillance 
of new devices.19
Industry was found to have a role in the develop-
ment and regulatory approval of the majority of 
devices identified. For devices developed in academia, 
collaboration with industry was associated with 
greater regulatory approval. Interestingly, the propor-
tion of 510(k), premarket approval, and other approv-
als that were awarded to industry and academia were 
comparable, suggesting that the greater regulatory 
approvals of devices developed by industry did not 
simply reflect a propensity for less disruptive and 
lower risk innovations. This finding supports efforts 
such as the Medical Device Innovation Consortium 
that facilitate collaboration among academia and 
industry to foster technology transfer.20 Collaboration 
between academia and industry may also contribute 
to improved surveillance of devices after regulatory 
approval has been received.
Comparison with other studies
In keeping with the present study, several other groups 
have also found limited publically available evidence to 
support the regulatory clearance and approval of new 
devices. Zuckerman et al evaluated the types of scien-
tific evidence used to support devices cleared using the 
510(k) pathway.5  Of the 50 devices included, eight had 
data to support the claim that they were substantially 
equivalent to a predicate device, and only three had 
data on safety or effectiveness. Chang et al found that 
even devices approved using the premarket approval 
pathway, which require considerably more scientific 
evidence, often had no published clinical trials.21  When 
trials are published, comparators are often absent, and 
details may differ substantially from the data submitted 
to the FDA.21 22
In a previous study we investigated the translation of 
new devices from the laboratory to first-in-human stud-
ies.9 In contrast with the present study we found that 
clinical rather than industry collaboration was the most 
important predictor of success; devices developed with 
clinical collaboration were over six times more likely to 
lead to a first-in-human study than those without. It is 
likely that this incongruity is the result of the varying 
role of clinical and industry collaboration through the 
device development pathway; early clinical studies may 
be more reliant on clinicians, and later regulatory 
approval more reliant on industry.
limitations of this study
We recognise several limitations to this study. We 
restricted our analysis to clinical studies of new medical 
devices reported in the biomedical literature. It is likely 
that the publication practices of academia and industry 
vary. We speculate that academia may be more moti-
vated to publish early clinical studies.
Our analysis may also have favoured more novel 
devices, which clinicians might have thought war-
ranted publication in the biomedical literature. The 
proportion of devices cleared through the 510(k) path-
way was therefore likely to be an underestimate.
We determined whether a device had regulatory 
approval using only the FDA medical device data-
bases. The proportion of medical devices receiving 
regulatory approval was therefore also undoubtedly 
an underestimate; in particular it is likely that licenses 
were granted from the European Union, which does 
not require any evidence of clinical value.11 The reason 
for selecting the FDA, rather than other licensing 
authorities, was because the FDA provides public 
databases and search engines that allowed for a sys-
tematic search strategy, the FDA acts as the central 
body for all medical devices receiving regulatory 
approval in the USA, and the USA represents the larg-
est medical device market in the world. We hypothe-
sise that most of the manufacturers of devices that 
received regulatory approval from another jurisdiction 
would have ultimately sought and obtained FDA 
approval within the timeframe of this study if they 
were successful.
We evaluated the contributions of academia and 
industry in the development of a device if a relation was 
described in the author affiliations, main text, or 
acknowledgments of the first published clinical study. 
We acknowledge that our cross sectional study design 
does not capture potential interactions between aca-
demia and industry during the early phase of a device’s 
development, such as the creation of spin-out compa-
nies or the licensing of intellectual property to industry. 
This study does not identify why industry was superior 
in obtaining regulatory approval compared with aca-
demia alone. One possible explanation is that the prof-
it-seeking motive of industry hones its choice as to 
which devices are pursued.
Conclusions
The optimal framework for the regulatory approval of 
medical innovations remains unclear. This study sug-
gests that many new devices do receive regulatory 
approval but often lack clinical trial data supporting 
their safety and effectiveness.
The IDEAL model makes several proposals for the 
staged introduction of innovations in surgery (and 
other disciplines that offer complex interventions), 
including randomised controlled trials to assess safety 
and effectiveness. At present, few relevant randomised 
controlled trials are published, and fewer still meet cur-
rent quality standards for optimal reporting. Changes in 
the regulatory approval of devices that would require 
trials for proof of safety and effectiveness might pro-
mote adherence to the IDEAL model.
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